MS Pharma, a leading generics company in the Middle East, has announced an agreement to acquire Greece-based Genepharm as part of an expansion drive into Europe and farther afield.
MS Pharma, a family-run generics firm operating across the Middle East, Turkey and Africa, said it has struck a deal to acquire 100% of the outstanding shares of Greek drugmaker Genepharm. The company called the acquisition an “important milestone in our growth plans.”
Based in Jordan’s capital Amman, MS Pharma says it is aiming to enlarge its geographic footprint and reach more customers...
Create an account to read this article
Already a subscriber?
Rumours are circulating that Aurobindo could be set to take ownership of Zentiva from current owner Advent in a $5bn transaction, which would represent one of the largest off-patent sector deals in some time.
Filed through the FDA’s 505(b)(2) hybrid new drug application pathway, Aquestive Therapeutics’ proposed Anaphylm (epinephrine) sublingual film has received major financial backing with a pair of funding deals.
Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.
Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.
Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.
Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.
With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.
